Peptic ulcer disease (PUD) is a condition characterized by localized mucosal damage in the stomach (gastric ulcer) or the proximal duodenum (duodenal ulcer), resulting from the corrosive effects of gastric acid and pepsin. The disease occurs due to an imbalance between aggressive factors, such as acid secretion and Helicobacter pylori (H. pylori) infection, and the protective mechanisms of the gastric mucosa^[1,4].

PUD affects 4-10% of the global population, with declining rates in developed nations but persistently high rates in Asia, Africa, and Latin America^[9]. In India, the prevalence of duodenal ulcers is higher than gastric ulcers, particularly in younger individuals, while gastric ulcers are more common in the elderly. H. pylori is implicated in over 80% of cases.^[8].

1. H. pylori Infection: The primary global cause of PUD, with virulence factors like urease and cytotoxins causing mucosal inflammation and ulceration, especially in developing nations^[4].

2. NSAID Use: Chronic NSAID use inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing mucosal protection^[1].

3. Lifestyle Factors: Smoking, alcohol, and poor diet exacerbate PUD risk, though less significantly than H. pylori and NSAID use^[6].

4. Hypersecretory Conditions: Zollinger-Ellison syndrome, caused by gastrin-secreting tumors, leads to excessive acid production and severe ulceration^[7].

5. Other Factors: Genetic predisposition, psychological stress, and non-H. pylori infections contribute to PUD^[2].

PUD prevalence has decreased in developed countries due to better sanitation, reduced H. pylori transmission, and PPI use. However, it remains prevalent in developing countries with high H. pylori infection rates^[1,4]. In India, H. pylori infection affects 50-90% of the population, especially in rural areas^[7].

Pathophysiology

1. Aggressive Factors: Excess gastric acid and pepsin activity contribute to ulcer formation, worsened by H. pylori’s effect on gastrin secretion^{[1, 2]}.

2. Impaired Mucosal Defense: Reduced mucus, bicarbonate, and blood flow weakens the mucosal barrier^[7].

3. Inflammation: H. pylori and NSAIDs trigger local inflammation, leading to further mucosal injury^[4].

Proton pump inhibitors (PPIs) are the first-line treatment for gastric ulcers, effectively suppressing gastric acid by inhibiting the H+/K+ ATPase enzyme.^[8]

Omeprazole (20–40 mg daily) is commonly preferred for its availability and efficacy. Other PPIs, such as esomeprazole, pantoprazole, and rabeprazole, offer similar healing rates (~90–95% within 4–8 weeks) at standard doses. All PPIs provide comparable results, with esomeprazole offering prolonged acid suppression in severe cases.^[9]

PPIs are highly effective in healing duodenal ulcers by suppressing gastric acid secretion. Standard treatment involves omeprazole (20–40 mg), esomeprazole (20–40 mg), pantoprazole (40 mg), or rabeprazole (20 mg) daily for 2–4 weeks. Healing rates are approximately 90–100%, with symptom relief often occurring within days. PPIs are superior to H2 blockers in promoting rapid healing and reducing relapse rates^[10].

For H. pylori-associated ulcers, PPIs are used in triple therapy to eradicate the infection and promote healing. A typical regimen includes a PPI (e.g., esomeprazole 20 mg twice daily) combined with clarithromycin and amoxicillin or metronidazole for 7–14 days. This approach improves eradication rates and significantly lowers the risk of recurrence. Quadruple therapy may be used for resistant strains, incorporating a PPI, bismuth subsalicylate, and two antibiotics^[11].

Chronic NSAID use impairs mucosal defense, leading to ulcers. PPIs like esomeprazole (20–40 mg daily) or pantoprazole (40 mg daily) are effective in both treatment and prevention. Studies show 80–90% healing rates within 4–8 weeks. PPIs also reduce gastrointestinal symptoms and prevent recurrence in patients requiring ongoing NSAID therapy. Co-prescription with NSAIDs is recommended for high-risk patients^[12].

Stress-related mucosal damage in critically ill patients can result in upper gastrointestinal bleeding. PPIs are used prophylactically to suppress gastric acid secretion and reduce the risk of ulcer formation. Both intravenous and oral PPIs (e.g., pantoprazole 40 mg or esomeprazole 40 mg daily) are effective. Prophylaxis is typically recommended in patients with risk factors such as mechanical ventilation or coagulopathy^[13].

Proton pump inhibitors (PPIs) are effective for short-term treatment of conditions like peptic ulcer disease and GERD, but prolonged use (beyond 8 weeks) may lead to risks. Long-term PPI use has been associated with nutrient deficiencies, particularly in magnesium, calcium, and vitamin B12, increasing the risk of fractures and other complications^[14]. Additionally, PPIs reduce stomach acid, elevating the risk of gastrointestinal infections such as Clostridium difficile and pneumonia^[15]. Prolonged PPI therapy is also linked to an increased risk of chronic kidney disease and acute kidney injury, especially in individuals with pre-existing renal conditions^[16]. Furthermore, some studies suggest that long-term PPI use, particularly after H. pylori infection, may raise the risk of gastric cancer . Despite these potential risks, PPIs remain a safe and effective treatment when used appropriately, and regular reassessment of long-term therapy is essential, especially for high-risk patients.

Recent advancements in proton pump inhibitors (PPIs) include novel formulations like dual delayed-release PPIs, such as dexlansoprazole, which offer extended acid suppression with once-daily dosing^[17]. Efforts are also underway to minimize long-term side effects, including fewer drug interactions and reduced risk of nutrient deficiencies^[18]. Additionally, more targeted delivery systems, such as enteric-coated PPIs, aim to improve drug stability and absorption in patients with gastric motility issues^[19]. Research into PPI-resistance and the development of potassium-competitive acid blockers (P-CABs) are providing promising alternatives for refractory conditions^[20].